Clementia

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Clementia and buy or sell other stocks, ETFs, and their options commission-free!

About CMTA

Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. 

CEO
Clarissa Desjardins, PhD
CEOClarissa Desjardins, PhD
Employees
Employees
Headquarters
Montréal, Québec
HeadquartersMontréal, Québec
Founded
2010
Founded2010
Employees
Employees

CMTA Key Statistics

Market cap
997.72M
Market cap997.72M
Price-Earnings ratio
-14.92
Price-Earnings ratio-14.92
Dividend yield
Dividend yield
Average volume
267.67K
Average volume267.67K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$26.73
52 Week high$26.73
52 Week low
$8.10
52 Week low$8.10

Stock Snapshot

With a market cap of 997.72M, Clementia(CMTA) trades at $26.35. The stock has a price-to-earnings ratio of -14.92.

During the trading day, Clementia(CMTA) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 267.67K.

The stock's 52-week range extends from a low of $8.10 to a high of $26.73.

The stock's 52-week range extends from a low of $8.10 to a high of $26.73.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.